Charles A. Sanders, M.D.

Chairman

introimage

Maria C. Freire, Ph.D.

President

Letter from the Chairman and President

The power of our organizational structure.

The Foundation for the National Institutes of Health (FNIH) was founded in 1996 by an act of Congress as a 501(c)(3) not-for-profit that can raise private funds in support of the NIH mission. In addition to raising funds—more than $750 million since our founding—the FNIH has excelled at creating innovative cross-sector partnerships in a neutral, pre-competitive environment to tackle large biomedical challenges with great urgency and efficiency. These partnerships offer a new way of generating the discoveries that improve health and change people’s lives for the better. The FNIH is a top-rated health charity, receiving Charity Navigator’s four-star rating for the seventh consecutive year in 2013.

Biomedical research never stands still. It is a field driven by the intellect and curiosity of scientists whose discoveries can enhance and protect the lives of people all over the world. Today, spurred by knowledge generated by the thousands of studies supported by the National Institutes of Health (NIH), we are experiencing an awe-inspiring era of scientific breakthroughs and revolutionary insights into the causes and potential solutions to disease and disability.

Paradoxically, NIH, America’s premier biomedical research institution, continues to cope with constrained budgets that critically erode our country’s ability to tap this remarkable opportunity. Industry and academia are not immune from similar challenges. As NIH Director Dr. Francis Collins wrote in the Washington Post in December 2013, we are “at a critical juncture—a moment of exceptional opportunities that demand exceptional attention if their promise is to be fully realized.”

An important game-changing strategy, one that helps redefine the landscape of biomedical research, one that blends priorities and mission, is helping to address these challenges. Creating alliances and partnerships that bring all the key players together—government, industry, the private sector, patient advocates and academic researchers—helps the biomedical community continue to take advantage of the unprecedented scientific opportunities now available. The Foundation for the National Institutes of Health (FNIH) is ideally positioned to create and manage complex collaborative efforts that streamline pathways to discovery and implementation for progress in support of greater knowledge that supports the mission of the NIH—“turning discovery into health.”

On these pages you will read about FNIH initiatives to find new biological markers of disease, to better prevent and treat traumatic brain injuries, to confront malnutrition and intestinal disorders in children of the world’s developing nations and much more. The FNIH is working to build a legacy of success. We are deeply proud of our accomplishments over the past year and we are even more excited about the years to come.

FNIH
at-a-Glance

Creating and managing a diverse portfolio or initiatives.
Developing diverse and uncommon collaborations.

OUR PARTNERSHIPS

Every day, the FNIH forges new models of collaboration where all partners can contribute and thrive. Our collective impact is much greater than what any single organization could achieve on its own.

fnih-graph

WHAT WE DO

The FNIH stands at the center of a wide portfolio of initiatives focused on a shared goal: advancing biomedical science to improve lives.

RESEARCH PARTNERSHIPS — We develop collaborations with top experts from government, industry, academia and the not-for-profit world and provide a neutral environment where we can work productively towards a common goal. Examples include:

NIH Research Portfolio — Supporting and raising funds for multiple projects initiated by the NIH, while also convening the right partners within and outside of the NIH.
Global Health — Coordinating and operating more than 50 collaborative projects in over 33 countries, including the Grand Challenges in Global Health (GCGH) supported by The Bill & Melinda Gates Foundation.
Biomarkers Consortium — Initiating and managing more than 16 projects funded with over $50 million in private dollars, designed to discover, develop and qualify biological markers to support new drug development, preventive medicine and medical diagnostics.

SYMPOSIA, EVENTS & EXHIBITS — We organize and facilitate more than 60 events each year, creating a forum for innovative thinkers in bioscience to share ideas and engage the public in disease and health awareness.

FELLOWSHIPS & AWARDS — We provide funding and training for early-career scientists, along with support and recognition for researchers whose findings have advanced biomedical science.

PROGRAM EXAMPLES

NIH Research: The Alzheimer’s Disease Neuroimaging Initiative created a new standard for cross-sector collaboration and data-sharing.

Global Health: Novel approach to control disease-spreading mosquitoes.

Biomarkers Consortium: The I-SPY Breast Cancer Trial is accelerating the development of targeted therapies.

Exhibit: The Smithsonian exhibition, Genome: Unlocking Life’s Code at the Natural Museum of History, opened in June 2013 to celebrate the anniversary of the sequencing of the human genome.

Award: The annual Lurie Prize in the Biomedical Sciences recognizes outstanding achievement by a promising scientist age 52 or younger.

2013
Highlights

A Unifying Force: Forging Uncommon Collaborations.
Channeling Resources: Achieving High-Impact Insights Worldwide.
Transformative Models: Shaping the Future of Biomedicine.

NEW PATHWAYS FOR DISCOVERY. Solving the greatest scientific challenges in biomedical research requires bold new thinking. We are uniquely positioned to help. We have the know-how to make collaborations thrive…creating environments that are open and neutral, garnering the necessary resources and developing new models.

A Unifying Force: Forging Uncommon Collaborations

A new collaboration focuses on traumatic brain injury

The FNIH has joined with the NIH and the National Football League—a founding partner, thanks to a $30 million donation—to form the Sports and Health Research Program (SHRP), which has taken on brain injury as its first challenge, including the study of the degenerative brain disease known as chronic traumatic encephalopathy, or CTE.

CTE results from repeated trauma to the brain and can lead to dementia, aggression, confusion and depression. Evidence of CTE has been found in the brains of deceased boxers, football players and other athletes. SHRP is bringing together researchers to define criteria for diagnosing CTE in brain tissue and also to determine whether the first signs of CTE can be diagnosed earlier in life through neuroimaging. In 2013, SHRP supported two major cooperative projects involving top CTE and brain injury researchers to understand long-term changes in the brain after head injury or concussions. Six additional pilot projects are working on new ways to diagnose and treat athletes who suffer concussions. SHRP’s work has critical implications for the 1.7 million Americans who suffer traumatic brain injuries each year, including amateur and professional athletes and combat soldiers.

A more efficient model to identify effective breast cancer drugs

Drugs such as tamoxifen and Herceptin® (trastuzumab) target specific characteristics of breast cancer cells. But they do not help all women.

The I-SPY 2 TRIAL, supported by the FNIH Biomarkers Consortium, created a way to evaluate multiple novel anti-cancer compounds in a single clinical trial structure, evaluating the effectiveness of the new treatment by measuring the shrinkage of the tumor prior to surgery. The trial assigns women with high-risk breast cancers to new treatments according to specific genetic or biological traits of that tumor, using adaptive randomization to improve these assignments within the trial and hasten the time to market for successful drugs.

Since 2010, seven compounds from five pharmaceutical companies have been part of I-SPY 2, of which two—neratinib and veliparib—have moved into wider testing (I-SPY 3).

Now a flourishing program, FNIH has turned I-SPY 2 over to QuantumLeap Healthcare Collaborative, a not-for-profit working with the University of California, San Francisco.

Unprecedented data sharing in Alzheimer’s research

As the Alzheimer’s Disease Neuroimaging Initiative (ADNI) approaches the end of its first decade, the partnership remains a gold standard for how academic, industry, advocacy and government partners can, together, advance biomedical research. Involving more than 25 partners coordinated by the FNIH, ADNI created an online, open-access database and image archive for all information collected by researchers.

In ADNI phase 1, this included MRI and PET scans, cerebrospinal fluid and other biosamples from 1,500 participants. Making the information available immediately helps speed everyone’s progress in identifying the biological markers (or biomarkers) that can help trace the progression from normal to mild cognitive impairment to Alzheimer’s Disease—the key to more accurate diagnosis and early intervention. ADNI data have provided the basis for numerous clinical trials and disease-modeling efforts. Several nations are now using similar approaches.

Phase 2, which will continue through 2015, follows phase 1 participants and has enrolled  an additional 750 people. The study has also expanded to include genetic testing, including whole-genome sequencing for more than  800 participants.

Channeling Resources: Achieving High-Impact Insights Worldwide

Insights into improving health for children in developing nations

Young children in resource-poor areas are often caught in a cycle of inadequate nutrition and frequent episodes of diarrhea caused by living in unsanitary conditions. Enteric (intestinal) diseases often undo the benefits of sufficient nutrition, leading to lifelong consequences, such as stunted growth and impaired cognitive development. The $40 million MAL-ED Network, a collaborative project supported by the Bill & Melinda Gates Foundation and managed by the FNIH in collaboration with the NIH Fogarty International Center, supports researchers at eight field sites in Africa, Asia and South America, who have been following more than 1,600 children (more than 200 at each site) since birth to understand how enteric pathogens, nutrition and other environmental factors are linked to physical growth, cognitive development and vaccine response.

Identifying biomarkers that predict growth faltering and/or impaired cognitive development will inform development of strategies for timely intervention. For example, MAL-ED recently found that elevated levels of three substances in the stool of infants may correlate with poorer growth over the subsequent six months, a result consistent in all eight sites, despite environmental differences. These biomarkers may hold promise to help identify children at greatest risk.

New targets for intervening in pulmonary disease

Chronic Obstructive Pulmonary Disease (COPD)—which includes chronic bronchitis and emphysema—affects more than
12 million Americans and is the country’s third leading cause of death. The disease progresses over time, suggesting that there may be points for early intervention to prevent full-blown COPD from developing. However, we do not understand the disease’s clinical course well enough to make that happen.

The SPIROMICS (SubPopulations and InteRmediate Outcome Measures in COPD Study) program brings together the National Heart, Lung and Blood Institute, the Food and Drug Administration, industry partners and multiple researchers across the country. The study is now enrolling subjects with COPD at 11 sites nationally and collecting blood samples, images, lung function tests and genetic information to determine disease subgroups and to identify biomarkers of disease progression and severity that will be useful as outcome measures in future clinical trials. FNIH coordinates the SPIROMICS External Scientific Board and hosted its meeting in the summer of 2013.

The first medical definition for age-related muscle loss

As people age, they lose skeletal muscle, which eventually can make them weaker, slower, more prone to fall and more dependent—at great cost to the healthcare system and society in general. This condition, called sarcopenia, affects nearly
1 in 3 people over 60 and half of those over age 80. At the moment, there is no standard for the diagnosis of sarcopenia, which limits our ability to understand how it develops and how it might be treated or prevented.

The FNIH Biomarkers Consortium Sarcopenia Project recently generated the first-ever, evidence-based definition for sarcopenia, bringing together the National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, academic institutions, the Food and Drug Administration, advocacy groups and five industry partners to analyze data from nine long-term epidemiologic studies involving more than 10,000 healthy people.

FNIH presented the definition in 2012 at a Sarcopenia Consensus Summit and five papers will be published in the spring of 2014. Approaching sarcopenia as a medical condition, rather than a natural outcome of aging, holds great promise for improving the lives of older people.

Transformative Models: Shaping the Future of Biomedicine

Novel approaches to evaluate urgently needed antibiotics

The threat posed by bacterial infections grows, as more strains develop resistance to the current arsenal of antibiotics. Yet, in 2010 regulatory approval for new antibiotics stalled, largely because the endpoints (outcome measures) used to judge effectiveness have been based on antiquated studies.

The FNIH Biomarkers Consortium helped establish consensus on what endpoints should be used in drug trials for Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Partners include the Food and Drug Administration, the NIH’s National Institute of Allergy and Infectious Diseases, the Infectious Diseases Society of America, pharmaceutical companies, biotechnology companies and academic researchers. The team identified two patient-reported outcome measures—symptom improvement within 3 to 5 days for pneumonia and control of lesion spread within 2 to 3 days for skin infection—that have been incorporated into regulatory decision-making criteria and clinical trials.

One new antibiotic has been approved for pneumonia and three for skin infection have cleared phase III testing—the result of well-designed clinical trials that drew on FNIH work. A full set of recommended outcome measures is under development, with completion expected by mid-2014.

A biological approach to stopping dengue fever

Found in 100 countries, with no vaccine and no cure, the mosquito-borne viral disease known as dengue fever is a significant global health threat. Using insecticides to control populations of the female Aedes aegypti mosquito, which spreads the virus, has failed to stop dengue; in fact, incidence has increased 30-fold in the past 50 years.

The FNIH’s Grand Challenges in Global Health, an initiative funded by the Bill & Melinda Gates Foundation, is supporting a global network of researchers who have found that infecting the mosquitoes with Wolbachia, a common bacterium found in many insects, can reduce mosquitoes’ ability to transmit the virus.

The method has shown great promise through a series of test releases in Australia and additional trials are underway in Vietnam, Indonesia and Brazil. Eliminate Dengue is one of several projects that are part of the FNIH’s Vector-based Control of Transmission: Discovery Research (VCTR) program, an offshoot of the Grand Challenges Initiative.

New inspiration for research on gender and Alzheimer’s

In early 2013, the FNIH came together with the Geoffrey Beene Foundation Alzheimer’s Initiative, to initiate a challenge to researchers worldwide, to better understand gender-based differences in the early cognitive decline that leads to Alzheimer’s Disease. Women have a greater risk of developing Alzheimer’s, partly because they live longer than men; however, we know little else about differences in how the disease affects the sexes.

Researchers were invited to “mine the data”—including those available through the Alzheimer’s Disease Neuroimaging Initiative (ADNI)—and present their own hypotheses. In November 2013, after a strict scientific and technical evaluation, Enrico Glaab, Ph.D., a researcher at the Luxembourg Centre for Systems Biomedicine, was selected as the winner. He received $50,000 to continue his study of USP9Y, a protein that is expressed at different levels in men’s and women’s brains and may afford men some protection. The decision was so close, however, that one of the contest’s sponsors, Sanofi, offered $50,000 to fund the second-place winners, Kimberly Glass, Ph.D., and John Quackenbush, Ph.D., of the Dana-Farber Cancer Institute.

Financial Highlights

2013 Revenues

[chart id=”1″]

2013 EXPENSES

[chart id=”2″]

TOTAL REVENUE AND SUPPORT	$60,373,946	$58,837,782
REVENUE AND SUPPORT	2013	2012
Contributions	$57,747,975	$57,116,586
Grants	887,026	1,338,963
Administrative fee	333,361	260,551
Government appropriations	500,000	514,000
Investment earnings	337,389	247,254
In-kind contributions	589,208	250,927
Donated services	43,000	41,000
Other revenue	150,775	343,501
Reduction of future pledges	(214,788)	(1,275,000)

EXPENSES AND CHANGES IN NET ASSETS

TOTAL PROGRAM SERVICES	$58,009,886	$47,789,765
PROGRAM SERVICES
Fellowships and training programs	$1,381,328	$1,325,295
Memorials, awards and events	1,299,278	1,246,180
Capital projects	38,754	35,100
Research partnerships	55,290,526	45,183,190

TOTAL SUPPORTING SERVICES	$3,456,183	$3,250,420
SUPPORTING SERVICES
Management and general	$3,352,175	$3,105,327
Fundraising	104,008	145,093

TOTAL EXPENSES

$61,466,069

$51,040,185

CHANGE IN NET ASSETS	$(1,092,123)	$7,797,597
NET ASSETS BEGINNING OF YEAR	92,230,541	84,432,944

NET ASSETS AT END OF YEAR

$91,138,418

$92,230,541

The Foundation's audited financial statements are available on request.

Contributors

Our Donors

All Foundation for the NIH (FNIH) donors play a critical role in providing the resources that are vital to our success. Unrestricted gifts allow us the flexibility to place them where they are most needed, from supporting core operations to developing new partnerships and emerging program ideas. Donors also can choose to restrict their gifts to one area of interest, such as a biomedical research program; a fellowship, lecture or symposium that trains scientists and helps them build their careers; or a specific laboratory or area of scientific research at the NIH.

The FNIH manages all private gifts with care and efficiency. Of every dollar spent, 94 cents are used to support programs and just six cents for administration and fundraising.

We gratefully acknowledge the following donors and partners who made gifts or pledges of $250 or more during 2013. Every attempt is made to list donors according to their wishes. Please call 301.402.5311 if you have any questions.

In 2013, FNIH received its
seventh consecutive four-star
rating by Charity Navigator.
This top ranking recognizes
that we execute our mission
in a “fiscally responsible way,
and outperform most
other charities.”

$5,000,000+ to $250,000

$5,000,000+

Bill & Melinda Gates Foundation ¹²

McKnight Brain Research Foundation ⁸

$2,500,000 – $4,999,999

Genentech, Inc. ⁷

Pfizer Inc ¹⁶

$1,000,000 – $2,499,999

Amgen, Inc. ¹¹

Eli Lilly and Company ¹⁴

Johnson & Johnson ¹³

Merck Sharp & Dohme Corp. ¹⁶

Novartis Pharmaceuticals Corporation ¹⁴

$500,000 – $999,999

Boehringer Ingelheim Pharmaceuticals, Inc. ⁵

Bristol-Myers Squibb ¹⁴

National Institutes of Health ¹⁸

Newport Foundation

Pharmaceutical Research and
Manufacturers of America ⁹

The Safeway Foundation ³

Sanofi ¹²

Takeda Pharmaceutical Company Limited ⁵

$250,000 – $499,999

AbbVie Inc.

Alzheimer’s Association ⁹

Biogen Idec ³

The Coca-Cola Company ⁶

GlaxoSmithKline ¹⁵

HSNi LLC

$249,999 to $50,000

$100,000 – $249,999

Arthritis Foundation, Inc. ⁴

AstraZeneca LP ¹²

Daiichi Sankyo, Inc. ⁴

Eisai Inc. ⁷

Flexion Therapeutics, Inc. ²

Forest Laboratories, Inc. ³

Foundation for Burkitt
Lymphoma Research

Fujirebio ²

Grifols ²

Healthcare Information and
Management Systems Society ²

Ikaria, Inc.

Institut De Recherches Internationales Servier ⁴

Ann Lurie ²

Mr. and Mrs. Joel S. Marcus ³

Merck Serono

Nippon Zoki Pharmaceuticals Co., Ltd. ²

Novo Nordisk A/S ²

The Bernard Osher Foundation ⁵

Piramal Imaging, GmbH ³

Roche ⁶

George and Trish Vradenburg ²
Co-Founders USAgainst Alzheimer’s

$50,000 – $99,999

Actelion Pharmaceuticals Ltd. ³

Alexandria Real Estate Equities, Inc.

American Association for Dental Research

AXA Research Fund ²

Dairy Research Institute ³

Geoffrey Beene Foundation
Alzheimer’s Initiative

Howard Hughes Medical Institute ²

New England Biolabs ⁵

Perrigo Company plc ²

PhRMA Foundation ⁶

Promega Corporation ³

Regeneron Pharmaceuticals, Inc.

Mrs. Lily Safra ¹²

$49,999 to $2,500

$25,000 – $49,999

American Society for Bone and
Mineral Research

Bausch & Lomb Incorporated ³

Bayer HealthCare Pharmaceuticals Inc.

BioClinica, Inc. ⁴

Biotechnology Industry Organization ⁶

Colgate-Palmolive Company

Danskin

James H. and Christina W. Donovan ²

GE Healthcare

Iconix Brand Group
In honor of Ari Goldman

IXICO Ltd. ²

Howard H. and Jacqueline K. Levine ³

Meso Scale Diagnostics, LLC. ⁵

Mr. and Mrs. Paul M. Montrone ¹⁶

NeuroRx ²

Otsuka American Pharmaceutical, Inc.

Andrew & Lillian A. Posey Foundation

Bill and Giuliana Rancic

SoBran, Inc. ³

SYNARC Inc. ⁶

Trius Therapeutics, Inc. ³

$2,500 – $4,999

Anonymous

Alliance for Aging Research ²

Ronald and Barbara Berke ⁴
In memory of Jennifer Berke

Gregg Bevensee ⁴

ChemoCentryx, Inc.

Anthony S. Fauci, M.D. and
Christine Grady, Ph.D.

Jim Fisher

Joseph H. and Cheryl L Kott
In honor of Temptime’s 25th anniversary

Donna Nichols ⁴

PNC Foundation

Lenore R. Salzman ¹⁶

SOHO Publishing Company ²

SunTrust Banks, Inc. ³

Samuel O. Thier, M.D. and Paula Thier ⁸

Alexander Trebek

Ullmann Family Foundation ⁵

Zerhouni Group LLC

$10,000 – $24,999

Janet B. Abrams 5
 In memory of Bernard Abrams

Alzheimer’s Drug Discovery Foundation

American College of Medical
Genetics and Genomics

AMS Foundation for the Arts,
Sciences and Humanities ⁹

Basilea Pharmaceutica International Ltd. ³

Peter D. and Karen N. Bell ²

Judy Belous
In memory of Effie Loomis

Buffy and William Cafritz ¹⁰

Chiesi Farmaceutici S.p.A. ⁴

Timothy Choate

Brad Cox
In honor of Ari Goldman

Crescendo Bioscience, Inc. ²

Friends of Cancer Research ⁴

Miles Gilburne and Nina Zolt ³

Hogan Lovells US LLP
In honor of John Porter

Estate of Jack Gramlich ³

Freda C. Lewis-Hall, M.D., F.A.P.A.

LUNGevity Foundation

Mars, Incorporated

Steve and Sherry Mayer

Mitsubishi Tanabe Pharma Corporation

Drs. Martin J. and Ann Murphy ⁸
In honor of Charles and Ann Sanders

Myriad RBM

Nabriva Therapeutics AG ³

Nestlé USA Inc.

Bob and Sally Newcomb ³

Nichols Family ⁴

OfficeMax Incorporated

Steven and Jann Paul ³

PepsiCo, Inc.

RottaPharm I Madaus ³

Dame Jillian Sackler ¹¹

Dr. and Mrs. Charles A. Sanders ¹⁷

Jane M. Sayer, Ph.D. ¹²

Dr. Ellen V. and Mr. Gerald R. Sigal ¹¹
In honor of John Porter

Simon Property Group ⁴

The Association for Frontotemporal Degeneration

United States Pharmacopeial Convention ³

USAgainst Alzheimer’s Network

$5,000 – $9,999

Anonymous

American Diabetes Association ⁴

American Orthopaedic Society for
Sports Medicine

Luther W. Brady, M.D. ⁷

California Dairy Research Foundation

Esther and James H. Cavanaugh ⁶

Centre for Proteomic & Genomic Research

Durata Therapeutics, Inc.

Foundation for Health Improvement
and Technology

Marjorie D. Fuller
In memory of Jean Fuller

General Mills, Inc.

Carol-Ann Harris

Laura and Chris Hazzard ⁵
In memory of Richard Curtin

Mike and Beth Hunkapiller ²

Kite Pharma, Inc. ²

Barbara Lazio
In memory of Carol Scher

Kelly and Adam Leight

Metabolon, Inc.

Dr. and Mrs. Garry A. Neil ²

Erik F. Neva ²

Kristin Neva ²

Radiological Society of North America ⁵

Research!America
In honor of John Porter

Robert E. Roberts, Ph.D. ⁵
In memory of Barbara Roberts

Nina Solarz ⁴
In memory of Stephen Solarz

University of British Columbia ³

Marica and Jan Vilcek ²

Steve and Chris Wilsey ⁵

Drs. Elias A. and Nadia Zerhouni

$2,499 to $500

$1,000 – $2,499

Anonymous (3)

Ronald A. and June L. Ahrens ²
In honor of Xavier Martin

Alnor Oil Company

Dr. and Mrs. William G. Barsan ⁴

Raghu Bellary

BH III LLC
In honor of Ari Goldman

Dr. Kathy and
Mr. Zachary T. Bloomgarden ⁵

Mr. Charles Cerf and
Dr. Cynthia E. Dunbar ³

Mark Chee, Ph.D. ²

Joe Bergera and Alice Cho

Thomas and Corrie Colter
In memory of Malcolm McDuffie

Stewart Daniels ⁵

Robert and Betsey Drucker ²

Marianne E. Durkin
In honor of Miller & Rider Group

Marilyn B. Einstein and Steven P. Sim

Jack A. Elias, M.D.

The Essence of Red Committee ³

Shirley Evans
In memory of Eleanor Frierson

Ronald G. Evens, M.D. ⁷
 In honor of John Gallin

Joseph M. Feczko, M.D. and
Leighton K. Gleicher ⁶

James M. Felser, M.D. ⁴

Shelagh Ferguson-Miller, Ph.D.

Drs. Ernesto I. and Maria C. Freire ²

Paul J. Gattini ²

Stanley and Eve Geller ³

Peggy J. Gerlacher ¹⁶
In memory of John Gerlacher

Eli Glatstein ¹⁰

Jane O. Graham ³

Margaret Grieve
In honor of Nina Solarz’ birthday

Gary and Lynn Grossman ³

Kay A. Hart ³

Harley Anderson Haynes, M.D. ⁴

Eric Hirschhorn and Leah Worthham ³

Eva C. Holtz ⁴

IQ Solutions ⁴

Kalidex Pharmaceuticals, Inc.

Bernard H. and Georgina E. Kaufman ⁴

U.S. Senator Amy Klobuchar

Sherry Lansing and William Friedkin

Jonathan D. Levine ³

Jean Linton ¹¹

Edison T. Liu, M.D., Ph.D.

John Madden

Debbie Magids
In honor of Ari Goldman

Margaret and James Malaro

Martin Goldman, L.L.C.
In honor of Ari Goldman

Ruth O. Mutch

Amy and John Porter ¹⁴

Sunny Raspet

Charles P. Rogers Beds

Robert and Marjorie Rosenberg ³

Estate of Frances H. Saupe ⁶

Robert C. and Dawn W. Schiff

Dr. and Mrs. Richard B. Silverman

Mark A. Spiteri ⁷

Russell W. Steenberg and
Patricia Colbert

Lynda Swann
In honor of Lanier Swann

Temptime Corporation ³

The Drs. Tremoulet ⁵

Jon and Kristin Vaver ⁶

Howard M. and Nancye C. Weisberg ⁵

Dr. Ann F. Welton ⁶

Stephanie J. Whang, M.D.

Michael and Lisa Nichols Whitten

Stewart K. Wilson ²

$500 – $999

Anonymous (3)

Drs. Bryan and Donna Arling ⁹

Association of American Medical Colleges ²
 In memory of Rod Ulane

Dr. and Mrs. Paul A. Berg

Robert A. Bergman ³
In memory of Arthur Schatzkin

Berroco, Inc. ²

Bnai Mitzvah Project 2013

Dan Balliet and Jan Carlson ⁵

Susan Castle
In honor of Ari Goldman

Classic Elite Yarns

The Community Foundation for
Greater Atlanta, Inc.

Janet S. DeGilio ⁴

James and Karen Gavic ⁴

Michael and Linda Goone

Ken and Yvette Guidry ⁷

Andrea Haslinger
 In honor of Gregory Papp and Lindsay Bailey

Henry Haslinger
In honor of Gregory Papp and Lindsay Bailey

Amy W. Hawthorne

Brian J. and Darlene Heidtke

Abigail Holtz

Arthur C. and Susan C. Horowitz ²

David Horowitz
In honor of Ari “Prefontaine” Goldman

Jimmy Beans Wool ²

Max Kantzer
In memory of Henry Kantzer &
In honor of Ari Goldman

Charles E. Kaufman Medical Fund ²

Ronald L. Krall, M.D. 2 ²
In memory of Vivian Krall

Jeremy Krasner ²

Arnold Lakind

Erica Joyce Lam ²

Dr. and Mrs. Ronald W. Lamont-Havers ⁴

Wei Li

Russell C. Libby, M.D. and
Mary Schmidt Libby, M.D. ²

London OpCo LLC

Mattlin Foundation ⁵

Charles McCormick ⁴

Luke McCrone ²

The McDuffie Family
 In memory of Malcolm McDuffie

Reverend and Mrs. Robert H. Naylor ⁴

New Belgium Brewing Co., Inc.

Northrop Grumman Corporation

Glen and Beverley Norton

Dr. Gilbert S. Omenn and
Mrs. Martha Darling ³

Matthew W. O’Neill ⁵

Matt and Robyn Nichols Painter ²
In memory of Jay Nichols

George Rudman
In honor of Ari Goldman

Dr. Michael Ryan and Dr. Linda Ryan

Howard K. Schachman ⁹
In memory of Ethel Schachman

Charles and Chris Sellers

Danny Shively ⁵

Walt and Rachel Sirene ²

Skacel Collection ²

Richard I. and Anastasia Smith

Shannon Stafford

Marta M. Ulane & Family
In memory of Rod Ulane

Richard and Tracy Nichols Waggoner
 In memory of Jay Nichols

David Wholley and Mary M. O’Crowley ²

Fred C. Williamson

Matthew Zimmerman ⁴

$250 to $499

Anonymous (8)

Acquanita Family

Ann Ashby and Ron Kopicki ³

Jill H. Barr ⁵
In memory of John Barr

Joan Beck ³

Charles Bish
In honor of Tom Russo

Robert Blelloch

Eric E. Bokker
In memory of Kelly Barr

Stuart Bondurant and Susan Ehringhaus ⁶

Gregory Brickhouse
In memory of Chris Battle

Damien P. Brouillard

Daniel Carucci, M.D., M.Sc., Ph.D. ⁴

Theresa Caruso

Brian and Eleanore Christiansen

Raymond W. Clement ⁵

Common Thread Group LLC
In honor of Ari Goldman

Craig Corbitt and Nancy Stoltz ⁴

Mary Frances Cotch and B. Fenton Hall ⁹

Susan G. Davis ⁵

Denise Interchangeable Knitting Needles ²

Carol and John Eddy ⁶
In honor of Garth Eddy

James P. Farrell
In honor of Nick Silano

Chris Flannery
In honor of Ari Goldman

Lorraine Ford

David A. Fryburg, M.D. ²

Jason and Gloria Garver ⁷

Jerry Gladstone
In honor of Ari Goldman

Drs. David Golan and Laura Green ³

Greenstein Neurology Associates PC

Joseph Grossman ²

Allen Gurevich
In honor of Ari Goldman

Marcia Hahn
In memory of Rod Ulane

Linford M. Hallman

Audray K. Harris, Ph.D.

Robert Heady

Thomas Heefner
In honor of Greg Papp and Lindsay Bailey

Arthur G. and Susan C. Horowitz ²

Sidney Ingber
In honor of Ari Goldman

Laurel Jacobson ⁴
In memory of Stephen Jacobson

Stephanie L. James, Ph.D. ³

JDM Consultants Int’l Ltd.
In honor of Ari Goldman

Pamela Jeffcoat ⁵

Richard Jonas and
Katherine Vernot-Jonas ⁶

Carrie Jones

Dr. and Mrs. Michael Kaliner

Victoria S. Kelsall
In memory of Jerry Jennings

Jody Kris ²

Melissa Kuskin ⁵
In memory of Bennett Bruce Camhi

Jeffrey Lackner

Thomas Lahr
In memory of Eleanor Frierson

Peter Lane

Gail Levine ³

Dr. Anne Alexander Marshall and
Mr. Davis Marshall ⁹

Cathleen Martin

John and Stacy Martin

Daniel Merced ²

Roger A. and Barbara Michaels ⁴

Moonlight Yarns

Namaste Inc. ²

Paul R. and Meredith K. Passmore
In memory of Charles William Scribner

Stephen J. Paulino ²

Plymouth Yarn Company ²

Gail Propp
In honor of Ari Goldman

Dr. Johng S. and Mary L. Rhim ²

James and Lora Rodenberg ⁴

Mr. Norman Rolnick

Michele Romano

In honor of Ari Goldman

Alissa Roston ²
In memory of Blanka Friedman

Kevin Sahl
In memory of Rod Ulane

John Shea

Calvert & Sally Simmons Foundation
In memory of Eleanor Frierson

Matthew Stapen
In honor of Ari Goldman

Lanier Swann ³

SweetGeorgia Yarns ²

Henry and Esther Swieca
In honor of Ari Goldman

Anthony Tassone ²

Ryan Temming

William Tolentino and Andre Bailey ⁵

Top Shelf Totes ²

Julie A. Tune ³

Arlene Urquhart ³

Paula J. Warrick ²

Robert C. Watson and Debra D. Petersen ³

Ingrid Wiley ⁵

Shari T. Wilson
In memory of David Feit

Howard and Julie Wolf-Rodda ⁷

Steven Wong

Joyce A. Yarington ¹⁰
In memory of Chris Harp

Joel Yesley ⁶

Aaron Young
In honor of Ari Goldman

Charles W. Zimmerman ⁶

Harry Zubli
In honor of Ari Goldman

GIVING SOCIETIES

DISCOVERY SOCIETY

The Foundation for the NIH acknowledges individuals who have supported our programs with a major gift in 2013 as members of the Discovery Society.

Anonymous (5)

Janet B. Abrams

Ronald A. and June L. Ahrens

Dr. and Mrs. William G. Barsan

Peter D. and Karen N. Bell

Raghu Bellary

Judy Belous

Ronald and Barbara Berke

Gregg Bevensee

Dr. Kathy and Mr. Zachary T. Bloomgarden

Luther W. Brady, M.D.

Buffy and William Cafritz

Esther and James H. Cavanaugh

Mr. Charles Cerf and Dr. Cynthia E. Dunbar

Mark Chee, Ph.D.

Joe Bergera and Alice Cho

Timothy Choate

Thomas and Corrie Colter

Brad Cox

Stewart Daniels

James H. and Christina W. Donovan

Robert and Betsey Drucker

Marianne E. Durkin

Marilyn B. Einstein and Steven P. Sim

Jack A. Elias, M.D.

Shirley Evans

Ronald G. Evens, M.D.

Anthony S. Fauci, M.D. and Christine Grady, Ph.D.

Joseph M. Feczko, M.D. and Leighton K. Gleicher

James M. Felser, M.D.

Shelagh Ferguson-Miller, Ph.D.

Jim Fisher

Drs. Ernesto I. and Maria C. Freire

Marjorie D. Fuller

Paul J. Gattini

Stanley and Eve Geller

Peggy J. Gerlacher

Miles Gilburne and Nina Zolt

Eli Glatstein

Jane O. Graham

Margaret Grieve

Gary and Lynn Grossman

Carol-Ann Harris

Kay A. Hart

Harley Anderson Haynes, M.D.

Laura and Chris Hazzard

Eric Hirschhorn and Leah Worthham

Eva C. Holtz

Mike and Beth Hunkapiller

Bernard H. and Georgina E. Kaufman

U.S. Senator Amy Klobuchar

Joseph H. and Cheryl L. Kott

Sherry Lansing and William Friedkin

Barbara Lazio

Kelly and Adam Leight

Howard H. and Jacqueline K. Levine

Jonathan D. Levine

Freda C. Lewis-Hall, M.D., FAPA

Jean Linton

Edison T. Liu, M.D., Ph.D.

Ann Lurie

John Madden

Debbie Magids

Margaret and James Malaro

Mr. and Mrs. Joel S. Marcus

Steve and Sherry. Mayer

Dr. and Mrs. Paul M. Montrone

Drs. Martin J. and Ann Murphy

Ruth O. Mutch

Dr. and Mrs. Garry A. Neil

Erik F. Neva

Kristin Neva

Bob and Sally Newcomb

Nichols Family

Donna Nichols

Bernard and Barbo Osher

Steven and Jann Paul

Amy and John Porter

Andrew & Lillian A. Posey

Bill and Giuliana Rancic

Sunny Raspet

Robert E. Roberts, Ph.D.

Robert and Marjorie Rosenberg

Dame Jillian Sackler

Mrs. Lily Safra

Lenore R. Salzman

Dr. and Mrs. Charles A. Sanders

Estate of Frances H. Saupe

Jane M. Sayer, Ph.D.

Robert C. and Dawn W. Schiff

Dr. Ellen V. and Mr. Gerald R. Sigal

Dr. and Mrs. Richard B. Silverman

Nina Solarz

Mark A. Spiteri

Russell W. Steenberg and Patricia Colbert

Lynda Swann

Samuel O. Thier, M.D. and Paula Thier

Alexander Trebek

The Drs. Tremoulet

Jon and Kristin Vaver

Marica and Jan Vilcek

George and Trish Vradenburg

Howard M. and Nancye C. Weisberg

Dr. Ann F. Welton

Stephanie J. Whang, M.D.

Michael and Lisa Nichols Whitten

Steve and Chris Wilsey

Stewart K. Wilson

Drs. Elias A. and Nadia Zerhouni

LEGACY SOCIETY

The Legacy Society recognizes individuals who have informed us that they have named the Foundation for the NIH as a beneficiary in their will or estate plan. These legacy gifts can support a specific NIH program, area of research or other identified need, or they may provide unrestricted support to the Foundation. We thank the following individuals who have named the Foundation as a beneficiary.

Anonymous (4)

Judy Belous

The Honorable and Mrs. William
McCormick Blair, Jr.

Paula L. and William C. Bradley

Michael Davis

Marjorie D. Fuller

Estate of Sallie Rosen Kaplan

Estate of Charles Harris

Patricia S. and Ken Kohlen

Drs. Zell and Emily Kravinsky

Patricia Nowosacki

Estate of Jennifer R. Price

Robert E. Roberts, Ph.D.

Estate of Frances H. Saupe

Jane M. Sayer, Ph.D.

Gail G. Thompson

Rita Visconte

Dr. and Mrs. Robert F. Wagner

Susan M. Wall, M.D.

HONORARIUM GIFTS

You can honor a friend or family member for an important occasion with a gift to the Foundation for the NIH. It is a wonderful way to send good wishes for a birthday or anniversary, thanks to a friend or doctor, or congratulations for retirement, a job well done or graduation. Please include the name and address of the individual being honored so that acknowledgement of your donation can be sent. In 2013, the Foundation received gifts in honor of the following individuals.

Lindsay Bailey

Sean Beinart

Peter J. Bush

Robert Drucker

Mark Dunn

Garth M. Eddy

John I. Gallin

Ari Goldman

Kathleen Haley

Kathleen P. Krisko

Andrew Leonhardt

Jeffrey W. Lindsey

Alan Lloyd

Meghan Lloyd

Jean Paul Martin

Marie-Reine Martin

Matthew W. O’Neill

Susanne N. O’Neill

Gregory Papp

John E. Porter

Kyla Riddle

Allen Robinson

Betsy Robinson

Steve Rohmann

Tom Russo

Charles A. Sanders

Ann Sanders

Rebecca L. Sheets

Nick Silano

Nina K. Solarz

Temptime Corporation

Kristen R. Thompson

Jack Wilson

Stuart H. Yuspa

MEMORIAL GIFTS

Contributions are given to the Foundation for the NIH at the request of family members in memory of loved ones. These generous contributions enhance our ability to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research, education and training. We extend our sympathies to the family and friends of those memorialized below.

Bernard W. Abrams

John L. Barr

Kelly S. Barr

Chris Battle

Karol Bell

Ethel Bennett

Jennifer Berke

George Bernard

Thurston H. Boyd

Paul Bruening

Bennett Camhi

Barbara Campbell

Colin Chignell

Richard Curtin

Darius Davis

Trudy Deutsch

Iva Dostanic

Joanie M. Dragland

David M. Feit

Jeffrey C. Fowler

Blanka Friedman

Eleanor Frierson

Carl Fryburg

Jean R. Fuller

Janice C. Gainer

John D. Gerlacher

Constance Gustafson

Chris Harp

Kelly M. Harty

James A. Henemyre

Sharon Hicks

Gary D. Hodgen

James V. Hudson

Aggie Hughes

Peter Hughes

Stephen W. Jacobson

David Johnson

McMillian N. Kabigting

Henry V. Kantzer

Meagan Kelly

Bruce Kenefick-Trish

Arthur Koch

Vivian L. Krall

Michael Krieger

Wesley J. LaPorte

Barbara L. Lazio

Stephen Liptak

Effie A. Loomis

Sandra Martin

Xavier Martin

George McCreedy

Malcolm B. McDuffie

Henry A. McLean

John N. Miller

Ron Muniz

Stan C. Nebinski

Jan Needham

Jay Nichols

Mohamed Tawakol Osman

Joseph Pate

William Penn

Lindsey Powell Rensch

Jennifer R. Price

Shirley Ray

Barbara A. Roberts

Dennis Rodenberg

Ethel L. Schachman

Arthur G. Schatzkin

Carol Scher

Lowell Schurman

Yin Schurman

Charles W. Scribner

Stephen Solarz

Joel H. Stumpp

Nathan W. Synan

Christopher Todd

Rod Ulane

Kimberly Underwood

Alice Waddell

Catherine J. Weikman

Charlotte Wong

William J. Yates

Funds & Endowments

We are grateful to the many individuals and organizations that have established funds or endowments at the FNIH to pay tribute to people and causes that matter to them. Such gifts provide essential ongoing support for research and education, as well as events in biomedicine at National Institutes of Health (NIH). Endowment gifts at all levels help to advance the pace of discovery and generate innovations that improve lives.

NAMED FUNDS

Named funds are created to support specific areas of research or fellowships, lectures or awards at the NIH.

John I. and Elaine K. Gallin Fund

This fund provides support for the Edmond J. Safra Family Lodge and to support patient and clinical research needs of the intramural research program at the National Institutes of Health.

Gramlich Melanoma Research Fund

This fund supports melanoma research at the NIH through an annual gift provided by the Jack Gramlich Foundation.

The Dr. Franklin A. Neva Memorial Fund

The Neva Fund was established by the family of Dr. Frank Neva, a former director of the NIAID Laboratory of Parasitic Diseases (LPD) at the NIH, to honor his memory and further his legacy. Dr. Neva was keenly interested in teaching and learning through case-based discussions and he transformed the LPD into a pre-eminent center for basic and clinical parasitology research and training.

Sayer Vision Research Fund

This fund supports the annual Sayer Lecture delivered by an investigator in the area of vision research, as well as the Sayer Vision Research Award, given to a promising independent investigator in the early stage of his or her research career in the Division of Intramural Research at the National Eye Institute. The fund was established by NIH research scientist Jane Sayer, in honor of her family and in memory of her parents, Winthrop and Laura Sayer.

Swanson Family Fellowship

The Swanson Family Fellowship supports research in TTF-1 mutation-causing benign chorea in the laboratory of infectious diseases under the direction of Steven M. Holland, M.D., Chief of the Laboratory of Clinical Infectious Diseases, NIAID.

MEMORIAL FUNDS

Memorial funds create a living legacy. In many cases a family member may request that friends and relatives make donations—rather than send flowers—to support a chosen cause in memory of a loved one. Families may wish to go one step further and establish a fund that embodies a loved one’s passion and spirit by making a significant investment in the Foundation.

Dr. John L. Barr Memorial Fund

This fund helps to support the Intramural Research Training Award Fellowship Program at the NIH Clinical Center’s Pain and Palliative Care Service. The goal of the fellowship is to conduct research on pain and palliative care and to encourage young investigators to become more familiar with the importance of this field of study.

Adam J. Berry Memorial Fund

This fund was established by Michael and Sue Berry in memory of their beloved son, Adam. Adam came from Australia to work as a research scientist at the National Cancer Institute (NCI). The fund commemorates his life and his enthusiasm for work by making it possible for promising young Australian scientists to travel to the United States and work at the NIH.

Edna Williams Curl and Myron R. Curl Fund
for Multiple Sclerosis Research

Established in 2007, this fund supports multiple sclerosis research at NIH.

John Laws Decker Memorial Fund

A former director of the NIH Clinical Center, Dr. John Laws Decker strived during his lifetime to accelerate important scientific research by linking research communications around the world. His dedication led the NIH to establish an annual lecture in his name. This fund, established by the Decker family, supports an event for the lecturer each year.

Tracy’s Toy Box

Established by the family in memory of Tracy Nadel, this fund purchases toys and activities for children staying at the Edmond J. Safra Family Lodge. These items help make their time at the Lodge more comfortable and pleasant.

Dean R. O’Neill Renal Cell Cancer
Research Fund

This fund supports a fellowship in the laboratory of tumor immunology headed by Richard Childs, M.D., at NHLBI. The postdoctoral cancer investigator funded by the program conducts research on the treatment of renal cell (or kidney) cancer. Family and friends of the late Dean O’Neill established the fund; more information can be found at www.renalcellcancer.org. The family also organizes the annual Boo! Run for Life 10K race and two-mile walk to support the fund. Information about the Boo! Run, held annually in October, can be found at www.boorunforlife.com.

Dr. Edward T. Rancic Memorial Fund

This fund supports a post-doctoral fellowship that focuses on renal cell cancer research in the laboratory of tumor immunology headed by Richard Childs, M.D., at NHLBI. The fellowship was established in memory of Dr. Edward Rancic by his family.

Dr. Anita Roberts Memorial Fund

Widely recognized as an outstanding mentor, encouraging and inspiring young scientists, Dr. Roberts was one of the first female laboratory chiefs at the NIH and ranked in the top 50 most-cited biological scientists in the world. Her family and laboratory colleagues established the fund to allow graduate students and post-doctoral fellows to present their work at a national meeting, typically the TGF-beta Keystone Symposium. These scholarships are a fitting tribute to Dr. Roberts’ passion for encouraging the career development of young scientists.

Robert Whitney Newcomb Memorial Fund

This fund was established by the family to remember Dr. Newcomb, who began his scientific career at the NIH as a high school summer intern in a laboratory at the NCI. The fund endows an annual lecture by a recognized expert in neuroscience, selected by the National Institute of Neurological Disorders and Stroke (NINDS). Honoring Dr. Newcomb’s own experience, it also provides for internships for high school students and fellowships at NINDS.

Stephen J. Solarz Memorial Fund

Nina Solarz established this fund in memory of her husband, former Congressman Steve Solarz, to support the research of Dr. David Schrump at NCI. Dr. Schrump’s pioneering research in the field of thoracic oncology led to the treatments that allowed Mr. Solarz to live years beyond what otherwise would have been possible. Before he died, Nina and her family dedicated themselves to supporting Dr. Schrump’s research so that other patients might benefit by even better treatments.

Stephen E. Straus Fund

Established by Bernard and Barbro Osher in 2006, this fund honors the founding director of the NIH’s National Center for Complementary and Alternative Medicine (NCCAM), the late Dr. Stephen E. Straus. It supports the Stephen E. Straus Distinguished Lecture in the Science of Complementary and Alternative Medicine, an annual lecture that brings leading figures in science and medicine to the NIH to speak about their perspective on the field. Open to the public, the lecture is videocast and archived on the NCCAM website.

ENDOWMENTS

Through these endowment gifts, donors ensure perpetual support for a variety of research and educational initiatives at FNIH. The annual investment income generated by an endowment fund supports program expenses, while the principal remains intact to ensure future funding.

Sallie Rosen Kaplan Fund for
Women Scientists in Cancer Research

The Kaplan Fund, established in 2000, provides support for the retention and mentoring of outstanding female cancer research scientists in the field. The program is managed by the National Cancer Institute.

Norman P. Salzman Memorial Fund

Dr. Salzman’s family, colleagues and friends remember the legacy of this noted pioneer in molecular biology through contributions to this fund, which supports the annual Norman P. Salzman Memorial Award and Symposium in Virology. The half-day symposium addresses key topics in virology and immunology and presents an award to a young researcher, in recognition of Dr. Salzman’s mentorship of so many younger scientists.

Endowments in support of the
Edmond J. Safra Family Lodge

Through endowment gifts, donors ensure perpetual support to the Edmond J. Safra Family Lodge for its operations and for the continued comfort of its guests.

GlaxoSmithKline Endowment

The GlaxoSmithKline Endowment supports programs and activities for families, including services that help residents stay in touch with employers and loved ones.

CarMollNat Muscular Dystrophy Endowment

The CarMollNat Muscular Dystrophy Endowment was established by Carol-Ann Harris in memory of her parents, Molly and Nathan Harris, and her brother, Merton Harris. The goals of the CarMollNat Endowment are to support research, science and wider knowledge, specifically for the many afflicted with Muscular Dystrophy (MD) and neuromuscular and neurogenetic diseases.The Endowment supports research at the Neurogenetics Branch of the National Institute of Neurological Disease and Stroke (NINDS).

Harry and Jeanette Weinberg Endowment

The Weinberg Endowment supports Edmond J. Safra Family Lodge operations and maintenance—ensuring that guests are provided a comfortable home away from home for years to come.

Additional Funds:

Jerry D. Jennings Memorial Fund

NCI Neuro Oncology Branch Fund

Pain and Palliative Care Program, Roxane Institute Fund

Research in Congenital Adrenal Hyperplasia

Board of Directors & Our Staff

Board of Directors

Charles A. Sanders, M.D. (Chairman)
Retired Chairman and CEO, Glaxo, Inc.

Mrs. William McCormick Blair, Jr. (Secretary)
Director Emeritus, Albert and Mary Lasker Foundation

Kathy Bloomgarden, Ph.D.
Chief Executive Officer, Ruder Finn, Inc.

Mrs. William (Buffy) N. Cafritz
Trustee, The John F. Kennedy Center
for the Performing Arts

Mr. James H. Donovan
Partner, Goldman Sachs & Company;
Adjunct Professor, University of Virginia

Joseph Feczko, M.D.
Retired Senior Vice President &
Chief Medical Officer, Pfizer Inc.

Maria C. Freire, Ph.D.
President and Executive Director,
Foundation for the National Institutes of Health

Mr. Miles Gilburne
Managing Member, ZG Ventures, LLC

Paul L. Herrling, Ph.D.
Chairman, Novartis Institute
for Tropical Disease

Ronald L. Krall, M.D.
Former Senior Vice-President and
Chief Medical Officer, GlaxoSmithKline

Ms. Sherry Lansing
Chief Executive Officer,
The Sherry Lansing Foundation

Freda C. Lewis-Hall, M.D.
Chief Medical Officer, Senior Vice President,
Pfizer Inc.

Edison T. Liu, M.D., Ph.D.
President and Chief Executive Officer,
The Jackson Laboratory

Ms. Ann Lurie
Lurie Holdings, Inc.,
Ann & Robert H. Lurie Foundation

Mr. Joel S. Marcus
Chairman, CEO and Founder,
Alexandria Real Estate Equities, Inc.

Mr. Steven C. Mayer
Former CEO and Co-Founder,
CoGenesys, Inc.

Paul M. Montrone, Ph.D. (Treasurer)
Chairman, Perspecta Trust

Martin J. Murphy, Jr., Ph.D.
Chairman & Chief Executive Officer,
AlphaMed Consulting, Inc.

Garry A. Neil, M.D.
Global Head R&D, Medgenics, Inc.

Steven M. Paul, M.D.
Director, Helen and Robert Appel
Alzheimer’s Disease Research Institute,
Weill Cornell Medical College

The Honorable John Edward Porter
(Vice Chairman for Policy)
Hogan Lovells US, LLP

Mrs. Jillian Sackler, D.B.E.
President and CEO, AMS Foundation
for the Arts, Sciences and Humanities

Mrs. Lily Safra
Chairwoman, The Edmond J. Safra
Philanthropic Foundation

Ellen V. Sigal, Ph.D.
Chairperson, Friends of Cancer Research

Solomon H. Snyder, M. D.
(Vice Chairman for Science)
Distinguished Service Professor of Neuroscience,
Johns Hopkins University School of Medicine

Ms. Nina K. Solarz
Former Executive Director of Peace Links
and the Fund for Peace

Samuel O. Thier, M.D.
Professor of Medicine and Health Care Policy,
Emeritus, Harvard Medical School,
Massachusetts General Hospital

Anne Wojcicki
Chief Executive Officer and Co-Founder,
23andMe

HONORARY DIRECTORS

Luther W. Brady, M.D.
Distinguished University Professor,
Drexel University College of Medicine

Patrick C. Walsh, M.D.
University Distinguished Service
Professor of Urology, Johns Hopkins
Medical Institutions

DIRECTOR EMERITUS

Paul Berg, Ph.D.
Cahill Professor in Biochemistry (Emeritus),
Stanford University School of Medicine

EX-OFFICIO

Francis S. Collins, M.D., Ph.D.
Director, National Institutes of Health

Margaret A. Hamburg, M.D.
Commissioner, Food and Drug Administration

Our Staff

President’s Office

Maria C. Freire, Ph.D.
President and Executive Director

Ann Ashby, M.B.A.
Deputy Executive Director

Andrea Baruchin, Ph.D.
Senior Advisor to the President

Erika Tarver
Senior Project Manager

Felicia Gray
Executive Assistant

Liz Johns
Executive Assistant

Kathy Guire
Operations Officer

Finance

Julie Tune, C.P.A., C.F.E.
Chief Financial Officer

Eva Coyne, C.P.A.
Controller

Cathy Martin, C.P.A.
Senior Accountant

Noemi B. Rodriguez
Staff Accountant

Peggy J. Gerlacher
Operations Associate

Events and Marketing

Laura Payne
Director

Jolie Mak
Events Manager

Jasmin Miles
Senior Events Coordinator

Andrea Hickman
Events Coordinator

Kai Yee
Digital Administrator

Development

Julie Wolf-Rodda, M.A.
Director of Development

Renee Bullion, M.P.A.
Partnership Development Officer

Elizabeth Dobbins
Partnership Development Officer

Rob Drucker, J.D., M.S.
Partnership Development Officer

Caite Gilmore
Partnership Development Officer

Jennifer Ilekis, M.P.A.
Partnership Development Officer

Paris L.A. Moore
Partnership Development Officer

Asante Shakuur
Partnership Development Officer

Will Tolentino
Development Systems Administrator

Anne Bradfield
Development Assistant

Will Whitaker
Development Intern

Science Administration

Stephanie James, Ph.D.
Director of Science and Director,
Grand Challenges in Global Health

Michael Gottlieb, Ph.D.
Deputy Director of Science

Dennis Lang, Ph.D.
Senior Program Coordinator, MAL-ED
(Contractor)

Karen Tountas, Ph.D.
Scientific Program Manager, MAL-ED

Susan Powell, M.T.S.
Senior Grants Manager

Susan Wiener, M.A.
Senior Project Manager

Gail Levine, M.A., C.R.C.C.
Scientific Program Manager

Anna Sambor, M.S.
Program Manager

Tiffany Francis
Executive Assistant

Biomarkers Consortium

David Wholley, M.S.
Director

Maria Vassileva, Ph.D.
Senior Scientific Program Manager,
Metabolic Disorders

Sonia Pearson-White, Ph.D.
Scientific Program Manager, Cancer

Judy Siuciak, Ph.D.
Scientific Program Manager, Neuroscience

Steven C. Hoffmann
Scientific Program Manager,
Inflammation and Immunity

Jessica Ratay, M.S.
Clinical Project Manager

Cheryl Melencio
Executive Assistant

About the art

New Pathways to Discovery

2013 Summary Annual Report

Who We Are